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INTRODUCTION: Acute Coronary Syndrome (ACS) is one of the main causes 
of morbidity and mortality in developed countries. Despite the research advances in 
recent years, ACS prevention and treatment strategies still suffer from significant 
limitations therefore new theoretical and technical approaches are required. The 
application of proteomics to ACS research constitutes an invaluable tool for the 
searching of new disease mechanisms, novel biomarkers and therapeutic targets, as well 
as to increase our understanding of the origin and development of this syndrome. In this 
work, we focused in the establishment of an individualized proteomic profile in non ST-
segment elevation ACS (NSTE-ACS) and ST-segment elevation ACS (STE-ACS) using 
two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry 
(MALDI-TOF/TOF). 
MATERIAL AND METHODS: EDTA plasma samples of 20 patients with 
NSTE-ACS, 20 patients with STE-ACS and 20 healthy controls recruited from the 
cardiology service of Hospital Virgen de la Salud were collected for this study. 2D-
DIGE experiments were carefully designed for STE-ACS vs healthy controls (n=6) and 
for NSTE-ACS vs healthy controls (n=5). Previously, all plasma samples were depleted 
using a Multi Affinity Removal column (MARS Hu-14, Agilent Technologies). Selected 
reaction monitoring (SRM) and immunoblotting were used for the validation process. 
RESULTS: 2-D Differential analysisrevealed 24 differentially expressed spots 
in plasma of NSTE-ACS patients (12 upregulated, 12 downregulated) and 47 in STE-
ACS (13 upregulated, 34 downregulated). The identification step is currently being 
completed and several of the identified proteins have already been validated. 
CONCLUSIONS: Our proteomic 2D-DIGE experiments demonstrate that STE-
ACS and NSTE-ACS can be defined by different and individualized proteomic profiles. 
These results could illuminate the understanding of changes implicated in the 
atherosclerotic process in both cases. We also expect to identify interesting proteins, 
which could be used as novel potential biomarkers for the prognosis and/or treatment of 
ACS in clinical practice. 
